US6458772B1
(en)
|
1909-10-07 |
2002-10-01 |
Medivir Ab |
Prodrugs
|
US3074929A
(en)
*
|
1955-08-11 |
1963-01-22 |
Burroughs Wellcome Co |
Glycosides of 6-mercaptopurine
|
GB924246A
(en)
|
1958-12-23 |
1963-04-24 |
Wellcome Found |
Purine derivatives and their preparation
|
US3116282A
(en)
|
1960-04-27 |
1963-12-31 |
Upjohn Co |
Pyrimidine nucleosides and process
|
GB984877A
(en)
|
1962-08-16 |
1965-03-03 |
Waldhof Zellstoff Fab |
Improvements in and relating to 6-halonucleosides
|
FR1498856A
(en)
|
1965-11-15 |
1968-01-10 |
|
|
GB1163103A
(en)
|
1965-11-15 |
1969-09-04 |
Merck & Co Inc |
Ribofuranosyl Purine Derivatives
|
FR1521076A
(en)
|
1966-05-02 |
1968-04-12 |
Merck & Co Inc |
Substituted purine nucleosides
|
DE1695411A1
(en)
|
1966-05-02 |
1971-04-15 |
Merck & Co Inc |
Substituted purine nucleosides and processes for their preparation
|
US3480613A
(en)
|
1967-07-03 |
1969-11-25 |
Merck & Co Inc |
2-c or 3-c-alkylribofuranosyl - 1-substituted compounds and the nucleosides thereof
|
DE2122991C2
(en)
*
|
1971-05-04 |
1982-06-09 |
Schering Ag, 1000 Berlin Und 4619 Bergkamen |
Process for the preparation of cytosine and 6-azacytosine nucleosides
|
USRE29835E
(en)
|
1971-06-01 |
1978-11-14 |
Icn Pharmaceuticals |
1,2,4-Triazole nucleosides
|
US3798209A
(en)
*
|
1971-06-01 |
1974-03-19 |
Icn Pharmaceuticals |
1,2,4-triazole nucleosides
|
US4022889A
(en)
*
|
1974-05-20 |
1977-05-10 |
The Upjohn Company |
Therapeutic compositions of antibiotic U-44,590 and methods for using the same
|
DE2508312A1
(en)
|
1975-02-24 |
1976-09-02 |
Schering Ag |
NEW PROCESS FOR THE PRODUCTION OF NUCLEOSIDES
|
US4058602A
(en)
|
1976-08-09 |
1977-11-15 |
The United States Of America As Represented By The Department Of Health, Education And Welfare |
Synthesis, structure, and antitumor activity of 5,6-dihydro-5-azacytidine
|
DE2757365A1
(en)
*
|
1977-12-20 |
1979-06-21 |
Schering Ag |
NEW PROCESS FOR THE PRODUCTION OF NUCLEOSIDES
|
DE2852721A1
(en)
|
1978-12-06 |
1980-06-26 |
Basf Ag |
METHOD FOR REPRESENTING POTASSIUM RIBONATE AND RIBONOLACTONE
|
US4239753A
(en)
|
1978-12-12 |
1980-12-16 |
The Upjohn Company |
Composition of matter and process
|
US4522811A
(en)
*
|
1982-07-08 |
1985-06-11 |
Syntex (U.S.A.) Inc. |
Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
|
FR2562543B1
(en)
|
1984-04-10 |
1987-09-25 |
Elf Aquitaine |
NOVEL CYCLIC PHOSPHONITES, THEIR PREPARATION AND APPLICATIONS
|
NL8403224A
(en)
*
|
1984-10-24 |
1986-05-16 |
Oce Andeno Bv |
DIOXAPHOSPHORINANS, THEIR PREPARATION AND THE USE FOR SPLITTING OF OPTICALLY ACTIVE COMPOUNDS.
|
JPS61204193A
(en)
|
1985-03-05 |
1986-09-10 |
Takeda Chem Ind Ltd |
Production of cytosine nuceoside
|
US6448392B1
(en)
|
1985-03-06 |
2002-09-10 |
Chimerix, Inc. |
Lipid derivatives of antiviral nucleosides: liposomal incorporation and method of use
|
US5223263A
(en)
*
|
1988-07-07 |
1993-06-29 |
Vical, Inc. |
Liponucleotide-containing liposomes
|
US4605659A
(en)
|
1985-04-30 |
1986-08-12 |
Syntex (U.S.A.) Inc. |
Purinyl or pyrimidinyl substituted hydroxycyclopentane compounds useful as antivirals
|
US4754026A
(en)
*
|
1985-06-04 |
1988-06-28 |
Takeda Chemical Industries, Ltd. |
Conversion of uracil derivatives to cytosine derivatives
|
DE3714473A1
(en)
|
1987-04-30 |
1988-11-10 |
Basf Ag |
CONTINUOUS PROCESS FOR EPIMERIZING SUGAR, ESPECIALLY FROM D-ARABINOSE TO D-RIBOSE
|
GB8719367D0
(en)
|
1987-08-15 |
1987-09-23 |
Wellcome Found |
Therapeutic compounds
|
US5246924A
(en)
|
1987-09-03 |
1993-09-21 |
Sloan-Kettering Institute For Cancer Research |
Method for treating hepatitis B virus infections using 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-ethyluracil
|
US4880784A
(en)
|
1987-12-21 |
1989-11-14 |
Brigham Young University |
Antiviral methods utilizing ribofuranosylthiazolo[4,5-d]pyrimdine derivatives
|
US5122517A
(en)
*
|
1988-06-10 |
1992-06-16 |
Regents Of The University Of Minnesota |
Antiviral combination comprising nucleoside analogs
|
GB8815265D0
(en)
*
|
1988-06-27 |
1988-08-03 |
Wellcome Found |
Therapeutic nucleosides
|
US6599887B2
(en)
|
1988-07-07 |
2003-07-29 |
Chimerix, Inc. |
Methods of treating viral infections using antiviral liponucleotides
|
US6252060B1
(en)
*
|
1988-07-07 |
2001-06-26 |
Nexstar Pharmaceuticals, Inc. |
Antiviral liponucleosides: treatment of hepatitis B
|
SE8802687D0
(en)
|
1988-07-20 |
1988-07-20 |
Astra Ab |
NUCLEOSIDE DERIVATIVES
|
US5744600A
(en)
*
|
1988-11-14 |
1998-04-28 |
Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic |
Phosphonomethoxy carbocyclic nucleosides and nucleotides
|
US5616702A
(en)
|
1988-11-15 |
1997-04-01 |
Merrell Pharmaceuticals Inc. |
2-'-ethenylidene cytidine, uridine and guanosine derivatives
|
US5705363A
(en)
*
|
1989-03-02 |
1998-01-06 |
The Women's Research Institute |
Recombinant production of human interferon τ polypeptides and nucleic acids
|
US5194654A
(en)
*
|
1989-11-22 |
1993-03-16 |
Vical, Inc. |
Lipid derivatives of phosphonoacids for liposomal incorporation and method of use
|
US5411947A
(en)
*
|
1989-06-28 |
1995-05-02 |
Vestar, Inc. |
Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
|
US5463092A
(en)
|
1989-11-22 |
1995-10-31 |
Vestar, Inc. |
Lipid derivatives of phosphonacids for liposomal incorporation and method of use
|
US6060592A
(en)
*
|
1990-01-11 |
2000-05-09 |
Isis Pharmaceuticals, Inc. |
Pyrimidine nucleoside compounds and oligonucleoside compounds containing same
|
US5200514A
(en)
*
|
1990-01-19 |
1993-04-06 |
University Of Georgia Research Foundation, Inc. |
Synthesis of 2'-deoxypyrimidine nucleosides
|
US5204466A
(en)
*
|
1990-02-01 |
1993-04-20 |
Emory University |
Method and compositions for the synthesis of bch-189 and related compounds
|
FR2662165B1
(en)
|
1990-05-18 |
1992-09-11 |
Univ Paris Curie |
BRANCHED NUCLEOSIDE DERIVATIVES, THEIR PREPARATION PROCESS AND THEIR USE AS MEDICAMENTS.
|
CA2083961A1
(en)
*
|
1990-05-29 |
1991-11-30 |
Henk Van Den Bosch |
Synthesis of glycerol di- and triphosphate derivatives
|
US5627165A
(en)
|
1990-06-13 |
1997-05-06 |
Drug Innovation & Design, Inc. |
Phosphorous prodrugs and therapeutic delivery systems using same
|
US5372808A
(en)
|
1990-10-17 |
1994-12-13 |
Amgen Inc. |
Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
|
US5543390A
(en)
|
1990-11-01 |
1996-08-06 |
State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University |
Covalent microparticle-drug conjugates for biological targeting
|
US5827819A
(en)
|
1990-11-01 |
1998-10-27 |
Oregon Health Sciences University |
Covalent polar lipid conjugates with neurologically active compounds for targeting
|
US5256641A
(en)
|
1990-11-01 |
1993-10-26 |
State Of Oregon |
Covalent polar lipid-peptide conjugates for immunological targeting
|
US5149794A
(en)
|
1990-11-01 |
1992-09-22 |
State Of Oregon |
Covalent lipid-drug conjugates for drug targeting
|
US5543389A
(en)
|
1990-11-01 |
1996-08-06 |
State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non Profit Organization |
Covalent polar lipid-peptide conjugates for use in salves
|
IL100502A
(en)
|
1991-01-03 |
1995-12-08 |
Iaf Biochem Int |
Pharmaceutical compositions containing cis-4-amino-1(hydroxymethyl-1,3-oxathiolan-5-yl)-1H-pyrimid-2-one nucleoside or its derivatives
|
JPH04266880A
(en)
|
1991-02-22 |
1992-09-22 |
Japan Tobacco Inc |
Production of 3-dpa-lactone
|
US5157027A
(en)
|
1991-05-13 |
1992-10-20 |
E. R. Squibb & Sons, Inc. |
Bisphosphonate squalene synthetase inhibitors and method
|
JPH0525152A
(en)
*
|
1991-07-22 |
1993-02-02 |
Japan Tobacco Inc |
Production of 3-dpa-lactone
|
US5554728A
(en)
|
1991-07-23 |
1996-09-10 |
Nexstar Pharmaceuticals, Inc. |
Lipid conjugates of therapeutic peptides and protease inhibitors
|
TW224053B
(en)
|
1991-09-13 |
1994-05-21 |
Paul B Chretien |
|
US5676942A
(en)
|
1992-02-10 |
1997-10-14 |
Interferon Sciences, Inc. |
Composition containing human alpha interferon species proteins and method for use thereof
|
US5821357A
(en)
|
1992-06-22 |
1998-10-13 |
Eli Lilly And Company |
Stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoropurine and triazole nucleosides
|
US5256797A
(en)
|
1992-06-22 |
1993-10-26 |
Eli Lilly And Company |
Process for separating 2-deoxy-2,2-difluoro-D-ribofuranosyl alkylsulfonate anomers
|
US5401861A
(en)
*
|
1992-06-22 |
1995-03-28 |
Eli Lilly And Company |
Low temperature process for preparing alpha-anomer enriched 2-deoxy-2,2-difluoro-D-ribofuranosyl sulfonates
|
US5606048A
(en)
*
|
1992-06-22 |
1997-02-25 |
Eli Lilly And Company |
Stereoselective glycosylation process for preparing 2'-Deoxy-2', 2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
|
US5371210A
(en)
|
1992-06-22 |
1994-12-06 |
Eli Lilly And Company |
Stereoselective fusion glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
|
DE4224737A1
(en)
|
1992-07-27 |
1994-02-03 |
Herbert Prof Dr Schott |
New cytosine analogues with lipophilic protected amino gps. - for treatment of cancer and virus diseases e.g. AIDS, are more protected against enzymatic des-amination and can be used in higher doses than unprotected cpds.
|
CA2105112C
(en)
|
1992-09-01 |
2005-08-02 |
Thomas C. Britton |
A process for anomerizing nucleosides
|
GB9226729D0
(en)
|
1992-12-22 |
1993-02-17 |
Wellcome Found |
Therapeutic combination
|
GB9307043D0
(en)
|
1993-04-05 |
1993-05-26 |
Norsk Hydro As |
Chemical compounds
|
US6156501A
(en)
|
1993-10-26 |
2000-12-05 |
Affymetrix, Inc. |
Arrays of modified nucleic acid probes and methods of use
|
US5587362A
(en)
|
1994-01-28 |
1996-12-24 |
Univ. Of Ga Research Foundation |
L-nucleosides
|
US5696277A
(en)
|
1994-11-15 |
1997-12-09 |
Karl Y. Hostetler |
Antiviral prodrugs
|
DK0747389T3
(en)
|
1994-12-13 |
2004-01-26 |
Taiho Pharmaceutical Co Ltd |
3'-substituted nucleoside derivatives
|
DE19513330A1
(en)
*
|
1995-04-03 |
1996-10-10 |
Schering Ag |
New process for the production of nucleosides
|
US5977061A
(en)
|
1995-04-21 |
1999-11-02 |
Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic |
N6 - substituted nucleotide analagues and their use
|
CA2231442A1
(en)
|
1995-09-07 |
1997-03-13 |
University Of Georgia Research Foundation, Inc. |
Therapeutic azide compounds
|
US5908621A
(en)
*
|
1995-11-02 |
1999-06-01 |
Schering Corporation |
Polyethylene glycol modified interferon therapy
|
US5980884A
(en)
|
1996-02-05 |
1999-11-09 |
Amgen, Inc. |
Methods for retreatment of patients afflicted with Hepatitis C using consensus interferon
|
GB9609932D0
(en)
*
|
1996-05-13 |
1996-07-17 |
Hoffmann La Roche |
Use of IL-12 and IFN alpha for the treatment of infectious diseases
|
CA2267279A1
(en)
*
|
1996-10-16 |
1998-04-23 |
Devron Averett |
Monocyclic l-nucleosides, analogs and uses thereof
|
CA2269213A1
(en)
*
|
1996-10-28 |
1998-05-07 |
The University Of Washington |
Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral rna
|
US6248878B1
(en)
*
|
1996-12-24 |
2001-06-19 |
Ribozyme Pharmaceuticals, Inc. |
Nucleoside analogs
|
US6472373B1
(en)
|
1997-09-21 |
2002-10-29 |
Schering Corporation |
Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection
|
US6172046B1
(en)
*
|
1997-09-21 |
2001-01-09 |
Schering Corporation |
Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
|
CA2322008C
(en)
*
|
1998-02-25 |
2011-06-28 |
Emory University |
2'-fluoronucleosides
|
US6312662B1
(en)
*
|
1998-03-06 |
2001-11-06 |
Metabasis Therapeutics, Inc. |
Prodrugs phosphorus-containing compounds
|
KR100389853B1
(en)
*
|
1998-03-06 |
2003-08-19 |
삼성전자주식회사 |
Method for recording and reproducing catalog information
|
US6833361B2
(en)
*
|
1998-05-26 |
2004-12-21 |
Ribapharm, Inc. |
Nucleosides having bicyclic sugar moiety
|
JP3839667B2
(en)
*
|
1998-06-08 |
2006-11-01 |
エフ.ホフマン−ラ ロシュ アーゲー |
Use of Peg-INF-alpha and ribavirin for the treatment of chronic hepatitis C
|
DE122007000062I1
(en)
|
1998-08-10 |
2007-12-20 |
Idenix Cayman Ltd |
Beta-L-2'-deoxynucleosides for the treatment of hepatitis B virus
|
US6444652B1
(en)
|
1998-08-10 |
2002-09-03 |
Novirio Pharmaceuticals Limited |
β-L-2'-deoxy-nucleosides for the treatment of hepatitis B
|
US6277830B1
(en)
|
1998-10-16 |
2001-08-21 |
Schering Corporation |
5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon
|
CA2252144A1
(en)
|
1998-10-16 |
2000-04-16 |
University Of Alberta |
Dual action anticancer prodrugs
|
US6458773B1
(en)
|
1998-11-05 |
2002-10-01 |
Emory University |
Nucleoside with anti-hepatitis B virus activity
|
EP1155017B1
(en)
|
1999-02-22 |
2003-01-15 |
Shire Biochem Inc. |
[1,8] naphthyridine derivatives having antiviral activity
|
US6831069B2
(en)
|
1999-08-27 |
2004-12-14 |
Ribapharm Inc. |
Pyrrolo[2,3-d]pyrimidine nucleoside analogs
|
WO2001018013A1
(en)
*
|
1999-09-08 |
2001-03-15 |
Metabasis Therapeutics, Inc. |
Prodrugs for liver specific drug delivery
|
US6566365B1
(en)
*
|
1999-11-04 |
2003-05-20 |
Biochem Pharma Inc. |
Method for the treatment of Flaviviridea viral infection using nucleoside analogues
|
MXPA02006156A
(en)
|
1999-12-22 |
2003-09-22 |
Metabasis Therapeutics Inc |
Novel bisamidate phosphonate prodrugs.
|
US6455508B1
(en)
|
2000-02-15 |
2002-09-24 |
Kanda S. Ramasamy |
Methods for treating diseases with tirazole and pyrrolo-pyrimidine ribofuranosyl nucleosides
|
US6495677B1
(en)
|
2000-02-15 |
2002-12-17 |
Kanda S. Ramasamy |
Nucleoside compounds
|
US7056895B2
(en)
*
|
2000-02-15 |
2006-06-06 |
Valeant Pharmaceuticals International |
Tirazole nucleoside analogs and methods for using same
|
EA200200778A1
(en)
*
|
2000-02-18 |
2003-06-26 |
Шайре Байокем Инк. |
METHOD OF TREATMENT OR PREVENTION OF HEPATITIS C INFECTION IN THE ORGANISM ORGANISM, PHARMACEUTICAL COMPOSITION AGAINST FLAVIVIRUS, CONNECTION OF FORMULA Ib - AN ACTIVE AGENT FOR THE TREATMENT OR PREVENTION OF EFFECTECH EFFECTURES Ib - AN ACTIVE AGENT FOR THE TREATMENT OR PREVENTION INEKEKHEKUSA Ib - AN ACTIVE AGENT FOR THE TREATMENT OR PROTECTION
|
DE60136620D1
(en)
*
|
2000-04-13 |
2009-01-02 |
Pharmasset Inc |
3 OR 2 HYDROXYMETHYL SUBSTITUTED NUCLEOSIDE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF VIRUS INFECTIONS
|
EP1282632A1
(en)
*
|
2000-04-20 |
2003-02-12 |
Schering Corporation |
Ribavirin-interferon alfa combination therapy for eradicating detectable hcv-rna in patients having chronic hepatitis c infection
|
MY164523A
(en)
*
|
2000-05-23 |
2017-12-29 |
Univ Degli Studi Cagliari |
Methods and compositions for treating hepatitis c virus
|
IL153078A0
(en)
*
|
2000-05-26 |
2003-06-24 |
Idenix Cayman Ltd |
Methods for treating hepatitis delta virus infection with beta-l-2' deoxy nucleosides
|
US6787526B1
(en)
|
2000-05-26 |
2004-09-07 |
Idenix Pharmaceuticals, Inc. |
Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides
|
EP1736478B1
(en)
*
|
2000-05-26 |
2015-07-22 |
IDENIX Pharmaceuticals, Inc. |
Methods and compositions for treating flaviviruses and pestiviruses
|
US6875751B2
(en)
*
|
2000-06-15 |
2005-04-05 |
Idenix Pharmaceuticals, Inc. |
3′-prodrugs of 2′-deoxy-β-L-nucleosides
|
US6815542B2
(en)
*
|
2000-06-16 |
2004-11-09 |
Ribapharm, Inc. |
Nucleoside compounds and uses thereof
|
US20030008841A1
(en)
*
|
2000-08-30 |
2003-01-09 |
Rene Devos |
Anti-HCV nucleoside derivatives
|
AU2002213343A1
(en)
|
2000-10-18 |
2002-04-29 |
Schering Corporation |
Ribavirin-pegylated interferon alfa HCV combination therapy
|
WO2002033128A2
(en)
|
2000-10-18 |
2002-04-25 |
Pharmasset Limited |
Multiplex quantification of nucleic acids in diseased cells
|
CN101862345B
(en)
*
|
2000-10-18 |
2014-06-04 |
吉利德制药有限责任公司 |
Modified nucleosides for treatment of viral infections and abnormal cellular proliferation
|
EP1366055A2
(en)
|
2000-12-15 |
2003-12-03 |
Pharmasset Limited |
Antiviral agents for treatment of flaviviridae infections
|
WO2002057287A2
(en)
*
|
2001-01-22 |
2002-07-25 |
Merck & Co., Inc. |
Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
|
US7105499B2
(en)
*
|
2001-01-22 |
2006-09-12 |
Merck & Co., Inc. |
Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
|
NZ540956A
(en)
|
2001-03-01 |
2007-01-26 |
Pharmasset Inc |
Method for the synthesis of 2',3'-dideoxy-2',3'-didehydronucleosides
|
GB0112617D0
(en)
*
|
2001-05-23 |
2001-07-18 |
Hoffmann La Roche |
Antiviral nucleoside derivatives
|
GB0114286D0
(en)
|
2001-06-12 |
2001-08-01 |
Hoffmann La Roche |
Nucleoside Derivatives
|
WO2003000200A2
(en)
|
2001-06-22 |
2003-01-03 |
Pharmasset Ltd. |
β-2'-OR 3'-HALONUCLEOSIDES
|
WO2003024461A1
(en)
*
|
2001-09-20 |
2003-03-27 |
Schering Corporation |
Hcv combination therapy
|
US20040006002A1
(en)
*
|
2001-09-28 |
2004-01-08 |
Jean-Pierre Sommadossi |
Methods and compositions for treating flaviviruses and pestiviruses using 4'-modified nucleoside
|
EP1569652A4
(en)
*
|
2001-12-14 |
2008-07-02 |
Pharmasset Inc |
N sp 4 /sp-acylcytosine nucleosides for treatment of viral iinfections
|
CN1646534A
(en)
*
|
2002-02-14 |
2005-07-27 |
法玛塞特有限公司 |
Modified fluorinated nucleoside analogues
|
WO2003072757A2
(en)
*
|
2002-02-28 |
2003-09-04 |
Biota, Inc. |
Nucleotide mimics and their prodrugs
|
US7247621B2
(en)
*
|
2002-04-30 |
2007-07-24 |
Valeant Research & Development |
Antiviral phosphonate compounds and methods therefor
|
EP1501850A2
(en)
*
|
2002-05-06 |
2005-02-02 |
Genelabs Technologies, Inc. |
Nucleoside derivatives for treating hepatitis c virus infection
|
AP2005003213A0
(en)
*
|
2002-06-28 |
2005-03-31 |
Univ Cagliari |
2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections.
|
JP2006505537A
(en)
|
2002-09-30 |
2006-02-16 |
ジェネラブス テクノロジーズ,インコーポレイテッド |
Nucleoside derivatives for treating hepatitis C virus infection
|
US7094768B2
(en)
*
|
2002-09-30 |
2006-08-22 |
Genelabs Technologies, Inc. |
Nucleoside derivatives for treating hepatitis C virus infection
|
HUE033832T2
(en)
*
|
2002-11-15 |
2018-01-29 |
Idenix Pharmaceuticals Llc |
2'-methyl nucleosides in combination with interferon and flaviviridae mutation
|
TWI332507B
(en)
*
|
2002-11-19 |
2010-11-01 |
Hoffmann La Roche |
Antiviral nucleoside derivatives
|
WO2004084453A2
(en)
|
2003-03-20 |
2004-09-30 |
Microbiologica Quimica E Farmaceutica Ltd. |
METHODS OF MANUFACTURE OF 2'-DEOXY-β-L-NUCLEOSIDES
|
US20040259934A1
(en)
|
2003-05-01 |
2004-12-23 |
Olsen David B. |
Inhibiting Coronaviridae viral replication and treating Coronaviridae viral infection with nucleoside compounds
|
US20040229839A1
(en)
|
2003-05-14 |
2004-11-18 |
Biocryst Pharmaceuticals, Inc. |
Substituted nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
|
ES2276311T3
(en)
*
|
2003-06-19 |
2007-06-16 |
F. Hoffmann-La Roche Ag |
PROCESS TO PRADERATE DERIVATIVES OF 4 '-AZIDONUCLEOSIDO.
|
US7144868B2
(en)
*
|
2003-10-27 |
2006-12-05 |
Genelabs Technologies, Inc. |
Nucleoside compounds for treating viral infections
|
US20050137141A1
(en)
*
|
2003-10-24 |
2005-06-23 |
John Hilfinger |
Prodrug composition
|
CA2543090A1
(en)
|
2003-10-27 |
2005-06-16 |
Genelabs Technologies, Inc. |
Nucleoside compounds for treating viral infections
|
US7157434B2
(en)
*
|
2003-10-27 |
2007-01-02 |
Genelabs Technologies, Inc. |
Nucleoside compounds for treating viral infections
|
CN101023094B
(en)
|
2004-07-21 |
2011-05-18 |
法莫赛特股份有限公司 |
Preparation of alkyl-substituted 2-deoxy-2-fluoro-d-ribofuranosyl pyrimidines and purines and their derivatives
|
DE602005015466D1
(en)
*
|
2004-08-23 |
2009-08-27 |
Hoffmann La Roche |
ANTIVIRAL 4'-AZIDONUCLEOSIDE
|
PL3109244T3
(en)
*
|
2004-09-14 |
2019-09-30 |
Gilead Pharmasset Llc |
Preparation of 2'fluoro-2'-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
|
US7414031B2
(en)
*
|
2004-11-22 |
2008-08-19 |
Genelabs Technologies, Inc. |
5-nitro-nucleoside compounds for treating viral infections
|
EP1853317A2
(en)
|
2005-02-09 |
2007-11-14 |
Migenix Inc. |
Compositions and methods for treating or preventing flaviviridae infections
|
DE102005012681A1
(en)
|
2005-03-18 |
2006-09-21 |
Weber, Lutz, Dr. |
New 1,5-dihydro-pyrrol-2-one compounds are HDM2 inhibitors, useful for treating e.g. stroke, heart infarct, ischemia, multiple sclerosis, Alzheimer's disease, degenerative disease, viral infection and cancer
|
AR056327A1
(en)
|
2005-04-25 |
2007-10-03 |
Genelabs Tech Inc |
NUCLEOSID COMPOUNDS FOR THE TREATMENT OF VIRAL INFECTIONS
|
CA2634749C
(en)
|
2005-12-23 |
2014-08-19 |
Idenix Pharmaceuticals, Inc. |
Process for preparing a synthetic intermediate for preparation of branched nucleosides
|